Source comparison
TB-500 Storage and Injection Site Rotation — Comparison
No Rotation (Same Site Repeatedly) 1–2 sites used exclusively Negligible. Continuous trauma High (30–50% develop nodules, persistent tenderness) Poor. Bioavailability drops 30–40% by week 3 Unacceptable for any research protocol requiring reproducible results.
This comparison does not assign a generated winner or score.
- No Rotation (Same Site Repeatedly)
- 1–2 sites used exclusively
- Negligible. Continuous trauma
- High (30–50% develop nodules, persistent tenderness)
- Poor. Bioavailability drops 30–40% by week 3
- Unacceptable for any research protocol requiring reproducible results. Causes localized fibrosis that compromises all subsequent injections.
- Minimal Rotation (4 Sites)
- 4 sites, 7–10 day intervals per site
- Partial. Insufficient for full resolution
- Moderate (15–25% develop mild site reactions)
- Variable. Absorption declines if protocol extends beyond 4 weeks
- Adequate for short protocols (≤4 weeks) but insufficient for extended timelines. Risk increases with smaller injection volumes or higher peptide concentrations.
- Standard Rotation (8 Sites)
- 8 sites, 14–16 day intervals per site
- Complete. Tissue fully recovers between uses
- Low (5–10% experience transient mild reactions)
- High. Consistent absorption maintained across 12+ week protocols
- Gold standard for most TB-500 research protocols. Balances ease of use with tissue preservation. Suitable for twice-weekly administration patterns.
- Extended Rotation (12+ Sites)
- 12–14 sites, 21+ day intervals per site
- Excessive recovery buffer
- Minimal (<5% experience any reactions)
- Optimal. Maximum bioavailability and minimal variance
- Required only for daily injection protocols or researchers with limited subcutaneous tissue mass. Adds complexity without meaningful benefit for standard twice-weekly TB-500 schedules.